{"success":true,"data":{"pressRelease":{"id":"157928","rtpr_id":"nGNXb76kB-20261001","ticker":"HELP","exchange":"NASDAQ","all_tickers":["HELP"],"title":"Helus Pharma Announces Completion of Legal Name Change","author":"Globe Newswire","published_at":"2026-10-01T11:30:00.228Z","article_body":"NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq:\nHELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage\npharmaceutical company committed to helping minds heal by developing novel\nserotonergic agonists (“NSAs”), is pleased to announce the Company’s\nlegal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.”\neffective October 1, 2026. The name change was approved by shareholders at the\nCompany’s annual and special meeting of shareholders held on September 22,\n2026. The name change follows the Company’s adoption of the business name\n“Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated\ntransformation from a clinical stage discovery and development company to a\ncommercial-ready pharmaceutical company.\n\nThe Company’s common shares will continue to trade on the Nasdaq Global\nMarket and Cboe Canada under the ticker symbol “HELP”. No action is\nrequired by existing shareholders, and outstanding share certificates and DRS\nstatements remain valid. The new CUSIP number assigned to the Company’s\ncommon shares is 423492107 and its new ISIN is CA4234921076.\n\nThe Company will continue to file documents under its updated profile on\nSEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange\nCommission on EDGAR at www.sec.gov.\n\nAbout Helus Pharma\n\nHelus Pharma Inc. is a clinical stage pharmaceutical company committed to\nhelping minds heal by developing proprietary NSAs, synthetic molecules\ndesigned to activate serotonin pathways that are believed to promote\nneuroplasticity. The Company’s proprietary NSAs are intended to address the\nlarge unmet need for people who suffer from depression, anxiety, and other\nmental health conditions.\n\nHelus Pharma is working to improve the treatment landscape through the\nintroduction of NSAs that aim to provide durable improvements in mental\nhealth. Helus Pharma is currently developing HLP003, a proprietary NSA, in\nPhase 3 clinical development for the adjunctive treatment of major depressive\ndisorder that has received Breakthrough Therapy Designation from the U.S. Food\nand Drug Administration and HLP004, also a proprietary NSA in Phase 2 for\ngeneralized anxiety disorder. Additionally, Helus Pharma has an extensive\nresearch portfolio of investigational NSAs.\n\nThe Company operates in Canada, the United States, the United Kingdom, and\nIreland. For Company updates and to learn more about Helus Pharma, visit\nwww.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus\nPharma™ is a trademark of Helus Pharma Corp.\n\nCautionary Notes and Forward-Looking Statements\n\nCertain statements in this news release relating to the Company are\nforward-looking statements and are prospective in nature. Forward-looking\nstatements are not based on historical facts, but rather on current\nexpectations and projections about future events and are therefore subject to\nrisks and uncertainties which could cause actual results to differ materially\nfrom the future results expressed or implied by the forward-looking\nstatements. These statements generally can be identified by the use of\nforward-looking words such as “may”, “should”, “could”,\n“intend”, “estimate”, “plan”, “anticipate”, “expect”,\n“believe” or “continue”, or the negative thereof or similar\nvariations. Forward-looking statements in this news release include statements\nregarding the Company’s plans to transform from a clinical stage discovery\nand development company to a commercial-ready pharmaceutical company; and the\nCompany’s plans to engineer proprietary drug discovery platforms, innovative\ndrug delivery systems, novel formulation approaches and treatment regimens for\nmental health conditions.\n\nAny forward-looking statements are based on reasonable assumptions and\nestimates of management of the Company at the time such statements were made.\nActual future results may differ materially as forward-looking statements\ninvolve known and unknown risks, uncertainties, and other factors which may\ncause the actual results, performance, or achievements of the Company to\nmaterially differ from any future results, performance, or achievements\nexpressed or implied by such forward-looking statements. Such factors, among\nother things, include: fluctuations in general macroeconomic conditions;\nfluctuations in securities markets; expectations regarding the size of the\npsychedelics market; the ability of the Company to successfully achieve its\nbusiness objectives; plans for growth; political, social and environmental\nuncertainties; employee relations; the presence of laws and regulations that\nmay impose restrictions in the markets where the Company operates;\nimplications of disease outbreaks on the Company’s operations; and the risk\nfactors set out in each of the Company’s management’s discussion and\nanalysis for the three months ended June 30, 2026 and the Company’s annual\ninformation form for the year ended March 31, 2026, which are available under\nthe Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S.\nSecurities and Exchange Commission on EDGAR at www.sec.gov. Although the\nforward-looking statements contained in this news release are based upon what\nmanagement of the Company believes, or believed at the time, to be reasonable\nassumptions, the Company cannot assure shareholders that actual results will\nbe consistent with such forward-looking statements, as there may be other\nfactors that cause results not to be as anticipated, estimated or intended.\nReaders should not place undue reliance on the forward-looking statements and\ninformation contained in this news release. The Company assumes no obligation\nto update the forward-looking statements of beliefs, opinions, projections, or\nother factors, should they change, except as required by law.\n\nThe Company makes no medical, treatment or health benefit claims about\nCompany’s proposed products. The U.S. Food and Drug Administration, Health\nCanada or other similar regulatory authorities have not evaluated claims\nregarding psilocin, psychedelic tryptamine, tryptamine derivatives or other\npsychedelic compounds. The efficacy of such products has not been confirmed by\napproved research. There is no assurance that the use of psilocin, psychedelic\ntryptamine, tryptamine derivatives or other psychedelic compounds can\ndiagnose, treat, cure or prevent any disease or condition. Rigorous scientific\nresearch and clinical trials are needed. If Helus Pharma cannot obtain the\napprovals or research necessary to commercialize its business, it may have a\nmaterial adverse effect on Company’s performance and operations.\n\nNeither Cboe Canada nor the Nasdaq Global Market stock exchange have approved\nor disapproved the contents of this news release and are not responsible for\nthe adequacy and accuracy of the contents herein.\n‍\nInvestor Contact:\nMatthew Beck\nastr partners\nManaging Partner\n(917) 415-1750\nMatthew.beck@astrpartners.com\n\nGabriel Fahel\nChief Legal Officer\nHelus Pharma\n1-866-292-4601\nirteam@helus.com – or – media@helus.com\n\nMedia Contact:\nVictoria Verdeja\nRXMD\nPublic Relations Director\n(212) 537-9495\nvverdeja@rxmedyn.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/575a4e81-a546-4d83-a092-e8f0df765900)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXb76kB-20261001","title":"Helus Pharma Announces Completion of Legal Name Change","author":"Globe Newswire","ticker":"HELP","created":"2026-10-01T11:30:00.228Z","tickers":["HELP"],"exchange":"NASDAQ","article_body":"NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq:\nHELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage\npharmaceutical company committed to helping minds heal by developing novel\nserotonergic agonists (“NSAs”), is pleased to announce the Company’s\nlegal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.”\neffective October 1, 2026. The name change was approved by shareholders at the\nCompany’s annual and special meeting of shareholders held on September 22,\n2026. The name change follows the Company’s adoption of the business name\n“Helus Pharma” on January 5, 2026 and reflects the Company’s anticipated\ntransformation from a clinical stage discovery and development company to a\ncommercial-ready pharmaceutical company.\n\nThe Company’s common shares will continue to trade on the Nasdaq Global\nMarket and Cboe Canada under the ticker symbol “HELP”. No action is\nrequired by existing shareholders, and outstanding share certificates and DRS\nstatements remain valid. The new CUSIP number assigned to the Company’s\ncommon shares is 423492107 and its new ISIN is CA4234921076.\n\nThe Company will continue to file documents under its updated profile on\nSEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange\nCommission on EDGAR at www.sec.gov.\n\nAbout Helus Pharma\n\nHelus Pharma Inc. is a clinical stage pharmaceutical company committed to\nhelping minds heal by developing proprietary NSAs, synthetic molecules\ndesigned to activate serotonin pathways that are believed to promote\nneuroplasticity. The Company’s proprietary NSAs are intended to address the\nlarge unmet need for people who suffer from depression, anxiety, and other\nmental health conditions.\n\nHelus Pharma is working to improve the treatment landscape through the\nintroduction of NSAs that aim to provide durable improvements in mental\nhealth. Helus Pharma is currently developing HLP003, a proprietary NSA, in\nPhase 3 clinical development for the adjunctive treatment of major depressive\ndisorder that has received Breakthrough Therapy Designation from the U.S. Food\nand Drug Administration and HLP004, also a proprietary NSA in Phase 2 for\ngeneralized anxiety disorder. Additionally, Helus Pharma has an extensive\nresearch portfolio of investigational NSAs.\n\nThe Company operates in Canada, the United States, the United Kingdom, and\nIreland. For Company updates and to learn more about Helus Pharma, visit\nwww.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus\nPharma™ is a trademark of Helus Pharma Corp.\n\nCautionary Notes and Forward-Looking Statements\n\nCertain statements in this news release relating to the Company are\nforward-looking statements and are prospective in nature. Forward-looking\nstatements are not based on historical facts, but rather on current\nexpectations and projections about future events and are therefore subject to\nrisks and uncertainties which could cause actual results to differ materially\nfrom the future results expressed or implied by the forward-looking\nstatements. These statements generally can be identified by the use of\nforward-looking words such as “may”, “should”, “could”,\n“intend”, “estimate”, “plan”, “anticipate”, “expect”,\n“believe” or “continue”, or the negative thereof or similar\nvariations. Forward-looking statements in this news release include statements\nregarding the Company’s plans to transform from a clinical stage discovery\nand development company to a commercial-ready pharmaceutical company; and the\nCompany’s plans to engineer proprietary drug discovery platforms, innovative\ndrug delivery systems, novel formulation approaches and treatment regimens for\nmental health conditions.\n\nAny forward-looking statements are based on reasonable assumptions and\nestimates of management of the Company at the time such statements were made.\nActual future results may differ materially as forward-looking statements\ninvolve known and unknown risks, uncertainties, and other factors which may\ncause the actual results, performance, or achievements of the Company to\nmaterially differ from any future results, performance, or achievements\nexpressed or implied by such forward-looking statements. Such factors, among\nother things, include: fluctuations in general macroeconomic conditions;\nfluctuations in securities markets; expectations regarding the size of the\npsychedelics market; the ability of the Company to successfully achieve its\nbusiness objectives; plans for growth; political, social and environmental\nuncertainties; employee relations; the presence of laws and regulations that\nmay impose restrictions in the markets where the Company operates;\nimplications of disease outbreaks on the Company’s operations; and the risk\nfactors set out in each of the Company’s management’s discussion and\nanalysis for the three months ended June 30, 2026 and the Company’s annual\ninformation form for the year ended March 31, 2026, which are available under\nthe Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S.\nSecurities and Exchange Commission on EDGAR at www.sec.gov. Although the\nforward-looking statements contained in this news release are based upon what\nmanagement of the Company believes, or believed at the time, to be reasonable\nassumptions, the Company cannot assure shareholders that actual results will\nbe consistent with such forward-looking statements, as there may be other\nfactors that cause results not to be as anticipated, estimated or intended.\nReaders should not place undue reliance on the forward-looking statements and\ninformation contained in this news release. The Company assumes no obligation\nto update the forward-looking statements of beliefs, opinions, projections, or\nother factors, should they change, except as required by law.\n\nThe Company makes no medical, treatment or health benefit claims about\nCompany’s proposed products. The U.S. Food and Drug Administration, Health\nCanada or other similar regulatory authorities have not evaluated claims\nregarding psilocin, psychedelic tryptamine, tryptamine derivatives or other\npsychedelic compounds. The efficacy of such products has not been confirmed by\napproved research. There is no assurance that the use of psilocin, psychedelic\ntryptamine, tryptamine derivatives or other psychedelic compounds can\ndiagnose, treat, cure or prevent any disease or condition. Rigorous scientific\nresearch and clinical trials are needed. If Helus Pharma cannot obtain the\napprovals or research necessary to commercialize its business, it may have a\nmaterial adverse effect on Company’s performance and operations.\n\nNeither Cboe Canada nor the Nasdaq Global Market stock exchange have approved\nor disapproved the contents of this news release and are not responsible for\nthe adequacy and accuracy of the contents herein.\n‍\nInvestor Contact:\nMatthew Beck\nastr partners\nManaging Partner\n(917) 415-1750\nMatthew.beck@astrpartners.com\n\nGabriel Fahel\nChief Legal Officer\nHelus Pharma\n1-866-292-4601\nirteam@helus.com – or – media@helus.com\n\nMedia Contact:\nVictoria Verdeja\nRXMD\nPublic Relations Director\n(212) 537-9495\nvverdeja@rxmedyn.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/575a4e81-a546-4d83-a092-e8f0df765900)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-01T11:30:00.296447521Z","server_sent_at_ms":1790854200296},"received_at":"2026-10-01T11:30:00.481Z","source_url":null},"analysis":{"id":"146574","press_release_id":"157928","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"ticker_change","narrative":"Helus Pharma announced its legal name change from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026, following shareholder approval on September 22.\n\nShares continue trading on Nasdaq and Cboe Canada under the unchanged ticker HELP, with new CUSIP 423492107 and ISIN CA4234921076; shareholders need take no action.\n\nThe company says the rebrand reflects its transition from clinical-stage developer toward a commercial-ready pharmaceutical company, with lead asset HLP003 in Phase 3 for adjunctive major depressive disorder under FDA Breakthrough Therapy Designation.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Administrative name-change completion for Cybin-to-Helus rebrand; ticker HELP unchanged."},"keyFigures":{"customDimensions":{"new_isin":"CA4234921076","new_cusip":"423492107","ticker_symbol_unchanged":"HELP"}},"namedEntities":{"people":[{"name":"Matthew Beck","role":"Managing Partner, astr partners (investor contact)"},{"name":"Gabriel Fahel","role":"Chief Legal Officer, Helus Pharma"},{"name":"Victoria Verdeja","role":"Public Relations Director, RXMD (media contact)"}],"products":["HLP003","HLP004"],"companies":[{"name":"Helus Pharma Inc.","ticker":"HELP","relationship":"filer (formerly Cybin Inc.)"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Administrative legal name change from Cybin Inc. to Helus Pharma Inc.; ticker symbol HELP is unchanged, trading continues uninterrupted, and no action is required by shareholders. Boilerplate corporate housekeeping with no financial impact."},"tickerRelevance":{"others":[],"primary":"HELP"},"globalImportance":12,"audienceRelevance":18,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"administrative name change","issuerAuthored":true,"financialImpact":"none"}},"event_type":"ticker_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Helus Pharma announced its legal name change from Cybin Inc. to Helus Pharma Inc., effective October 1, 2026, following shareholder approval on September 22.\n\nShares continue trading on Nasdaq and Cboe Canada under the unchanged ticker HELP, with new CUSIP 423492107 and ISIN CA4234921076; shareholders need take no action.\n\nThe company says the rebrand reflects its transition from clinical-stage developer toward a commercial-ready pharmaceutical company, with lead asset HLP003 in Phase 3 for adjunctive major depressive disorder under FDA Breakthrough Therapy Designation.","key_figures":{"customDimensions":{"new_isin":"CA4234921076","new_cusip":"423492107","ticker_symbol_unchanged":"HELP"}},"named_entities":{"people":[{"name":"Matthew Beck","role":"Managing Partner, astr partners (investor contact)"},{"name":"Gabriel Fahel","role":"Chief Legal Officer, Helus Pharma"},{"name":"Victoria Verdeja","role":"Public Relations Director, RXMD (media contact)"}],"products":["HLP003","HLP004"],"companies":[{"name":"Helus Pharma Inc.","ticker":"HELP","relationship":"filer (formerly Cybin Inc.)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-01T11:30:05.141Z","global_importance":12,"audience_relevance":18,"importance_components":{"tickerTier":"small-cap clinical-stage biotech","eventGravity":"administrative name change","issuerAuthored":true,"financialImpact":"none"}},"durationMs":4623,"modelName":"glm-5.3-flashx"}}